Invest Yadnya's all Articles

Sales volume grew by 17.8% to 13.2 Cr. Cases in Q4 CY2022 due to strong international performance along with increased realizations primarily due to price hikes in select SKUs, rationalized discounts/incentives, and improvement in the mix of smaller SKUs (250ml) especially the energy drink - Sting which has a higher net realization. Sting is now 9.6% of total sales volumes in India

Revenue from operations increased by 14% YoY (12% in constant currency), mainly driven by underlying growth of 15% in India Business, 6% in International Business, and 9% in Non-Branded Business.

Revenue increased by 17.54% during the quarter to Rs.4,786 Cr on back of strong improvements in realizations and cargo volume growth.

Topline grew by 17.17% on Y-o-Y basis due to better revenue mix, normalization of medical tourism and rise in pharmacy sales.

Deepak Nitrite Reported Strong topline performance was driven by maintaining leadership in market share and geographies.

Five key facilities Mohali, FMRI, Shalimar Bagh, BG Road and Mulund, continue to improve and are operating at a decent occupancy level so company expects to grow there further.

Revenue from operations for the business increased due to strong performance in exports, aftermarket and industrial business.

There was an EBITDA loss of Rs. 62 crore due to low capacity utilisation in Germany and North America. Total capacity at 7.5 million tonnes per annum which is operating at ~50% (old plant at 70% and new at 30%). The company expects performance to improve Q4FY23 and get better in FY24.

In Q3FY23, revenue increased by 7.4% YoY. The growth was driven by robust growth in Online channels and Direct to Customers channel demonstrated an YOY growth of 45.6% demand.

Revenue has increased QoQ (3.96%) but revenue on YoY has reduced marginally 1.74%. Increase in the revenue QoQ came from advertisement revenue which has increased by 5% and subscription revenue has increased by 9%.